A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile

Antiviral Research

Volumn 98, Issue 3, 2013, Pages 365-372

  Okello, Maurice O ^a   Mishra, Sanjay ^a   Nishonov, Malik ^a   Mankowski, Marie K ^b   Russell, Julie D ^b   Wei, Jiayi ^b   Hogan, Priscilla A ^b   Ptak, Roger G ^b   Nair, Vasu ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Anti HIV; CYP UGT profiles; Drug drug interactions; Integrase; Resistance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS INTEGRASE INHIBITOR; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG; URIDINE 5' DIPHOSPHO GLUCURONOSYLTRANSFERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GLUCURONOSYLTRANSFERASE; HELA CELLS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HIV-2; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; MUTATION; PYRIDINES; PYRROLIDINES; SIMIAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MYCOBACTERIUM TUBERCULOSIS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84877244757     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.005     Document Type: Article

References (46)

1. Abimiku A.G., Stern T.L., Zwandor A., Markham P.D., Calef C., Kyari S., Saxinger W.C., Gallo R.C., Robertguroff M., Reitz M.S. Subgroup-G HIV type-1 isolates from Nigeria. AIDS Res. Hum. Retroviruses. 1994, 10:1581-1583.
2. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
3. Buckheit R.W., Swanstrom R. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse-transcriptase activity. AIDS Res. Hum. Retroviruses. 1991, 7:295-303.
4. Daniel M.D., Letvin N.L., King N.W., Kannagi M., Sehgal P.K., Hunt R.D., Kanki P.J., Essex M., Desrosiers R.C. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985, 228:1201-1204.
5. Cytochrome P450: Structure, Mechanism, and Biochemistry 2005, Kluwer Academic/Plenum, New York. third ed. P.R. de Montellano (Ed.).
6. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science 2010, 328:856-861.
7. Frankel A.D., Young J.A.T. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67:1-25.
8. Gao F., Robertson D.L., Carruthers C.D., Morrison S.G., Jian B.X., Chen Y.L., Barre-Sinoussi F., Girard M., Srinivasan A., Abimiku A.G., Shaw G.M., Sharp P.M., Hahn B.H. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:5680-5698.
9. Gao F., Yue L., Craig S., Thornton C.L., Robertson D.L., Mccutchan F.E., Bradac J.A., Sharp P.M., Hahn B.H., Osmanov S., Belsey E.M., Heyward W., Esparza J., Galvaocastro B., Vandeperre P., Karita E., Wasi C., Sempala S., Tugume B., Biryahwaho B., Rubsamenwaigmann H., Vonbriesen H., Esser R., Grez M., Holmes H., Newberry A., Ranjbar S., Tomlinson P., Bradac J., Mccutchan F., Louwagie J., Hegerich P., Lopez-Galindez C., Olivares I., Dopazo J., Mullins J.I., Delwart E.L., Bachmann H.M., Goudsmit J., Dewolf F., Saragosti S., Schochetman G., Kalish M., Luo C.C., George R., Pau C.P., Weber J., Cheingsongpopov R., Kaleebu P., Nara P., Fenyo E.M., Albert J., Myers G., Korber B. Genetic-variation of HIV type-1 in 4 world-health-organization-sponsored vaccine evaluation sites - generation of functional envelope (Glycoprotein-160) clones representative of sequence subtype-A, subtype-B, subtype-C, and subtype-E. AIDS Res. Hum. Retroviruses. 1994, 10:1359-1368.
10. Goethals O., Clayton R., Van Ginderen M., Vereycken I., Wagemans E., Geluykens P., Dockx K., Strijbos R., Smits V., Vos A., Meersseman G., Jochmans D., Vermeire K., Schols D., Hallenberger S., Hertogs K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82:10366-10374.
11. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
12. Haren L., Ton-Hoang B., Chandler M. Integrating DNA: transposases and retroviral integrases. Annu. Rev. Microbiol. 1999, 53:245-281.
13. Jagodzinski L.L., Wiggins D.L., McManis J.L., Emery S., Overbaugh J., Robb M., Bodrug S., Michael N.L. Use of calibrated viral load standards for group m subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J. Clin. Microbiol. 2000, 38:1247-1249.
14. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J. Intern. Med. 2010, 268:530-539.
15. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., Azrolan N., Iwamoto M., Wagner J.A., Wenning L.A. Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35:1657-1663.
16. Keele B.F., Van Heuverswyn F., Li Y.Y., Bailes E., Takehisa J., Santiago M.L., Bibollet-Ruche F., Chen Y.L., Wain L.V., Liegeois F., Loul S., Ngole E.M., Bienvenue Y., Delaporte E., Brookfield J.F.Y., Sharp P.M., Shaw G.M., Peeters M., Hahn B.H. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
17. Kiang T.K.L., Ensom M.H.H., Chang T.K.H. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 2005, 106:97-132.
18. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human-immunodeficiency-virus with a sensitive cell-line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 1992, 66:2232-2239.
19. Kobayashi M., Yoshinaga T., Seki T., Wakasa-Morimoto C., Brown K.W., Ferris R., Foster S.A., Hazen R.J., Miki S., Suyama-Kagitani A., Kawauchi-Miki S., Taishi T., Kawasuji T., Johns B.A., Underwood M.R., Garvey E.P., Sato A., Fujiwara T. In vitro antiretroviral properties of S/GSK1349572, a next-generation hiv integrase inhibitor. Antimicrob. Agents Chemother. 2011, 55:813-821.
20. Kortagere S., Madani N., Mankowski M.K., Schon A., Zentner I., Swaminathan G., Princiotto A., Anthony K., Oza A., Sierra L.J., Passic S.R., Wang X.Z., Jones D.M., Stavale E., Krebs F.C., Martin-Garcia J., Freire E., Ptak R.G., Sodroski J., Cocklin S., Smith A.B. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J. Virol. 2012, 86:8472-8481.
21. Krishnan L., Engleman A. Retroviral integrase proteins and HIV-1 DNA integration. J. Biol. Chem. 2012, 287:40858-40866.
22. Mathias A.A., West S., Hui J., Kearney B.P. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin. Pharmacol. Ther. 2009, 85:64-70.
23. Michael N.L., Herman S.A., Kwok S., Dreyer K., Wang J., Christopherson C., Spadoro J.P., Young K.K.Y., Polonis V., McCutchan F.E., Carr J., Mascola J.R., Jagodzinsi L.L., Robb M.L. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J. Clin. Microbiol. 1999, 37:2557-2563.
24. Min S., Song I., Borland J., Chen S.G., Lou Y., Fujiwara T., Piscitelli S.C. Pharmacokinetics and safety of S/GSK1349572, a next-generation hiv integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 2010, 54:254-258.
25. Miners J.O., Smith P.A., Sorich M.J., McKinnon R.A., Mackenzie P.I. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. 2004, 44:1-25.
26. Nair V., Chi G., Ptak R., Neamati N. HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. J. Med. Chem. 2006, 49:445-447.
27. Nair V., Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 2007, 17:277-295.
28. Owen S.M., Ellenberger D., Rayfield M., Wiktor S., Michel P., Grieco M.H., Gao F., Hahn B.H., Lal R.B. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 1998, 72:5425-5432.
29. Pommier Y., Johnson A.A., Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4:236-248.
30. Ptak R.G., Gallay P.A., Jochmans D., Halestrap A.P., Ruegg U.T., Pallansch L.A., Bobardt M.D., de Bethune M.P., Neyts J., De Clercq E., Dumont J.M., Scalfaro P., Besseghir K., Wenger R.M., Rosenwirth B. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob. Agents Chemother. 2008, 52:1302-1317.
31. Ptak R.G., Gentry B.G., Hartman T.L., Watson K.M., Osterling M.C., Buckheit R.W., Townsend L.B., Drach J.C. Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef. Antimicrob. Agents Chemother. 2010, 54:1512-1519.
32. Reuman E.C., Bachmann M.H., Varghese V., Fessel W.J., Shafer R.W. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob. Agents Chemother. 2010, 54:934-936.
33. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
34. Seo B.I., Uchil V.R., Okello M., Mishra S., Ma X.H., Nishonov M., Shu Q.N., Chi G.C., Nair V. Discovery of a potent hiv integrase inhibitor that leads to a prodrug with significant anti-HIV activity. ACS Med. Chem. Lett. 2011, 2:877-881.
35. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82:764-774.
36. Smith S.D., Shatsky M., Cohen P.S., Warnke R., Link M.P., Glader B.E. Monoclonal-antibody and enzymatic profiles of human-malignant lymphoid-T cells and derived cell-lines. Cancer Res. 1984, 44:5657-5660.
37. Strassburg C.P., Strassburg A., Kneip S., Barut A., Tukey R.H., Rodeck B., Manns M.P. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002, 50:259-265.
38. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Paz O.G., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
39. Taktakishvili M., Neamati N., Pommier Y., Pal S., Nair V. Recognition and inhibition of HIV integrase by novel dinucleotides. J. Am. Chem. Soc. 2000, 122:5671-5677.
40. Trono D., Van Lint C., Rouzioux C., Verdin E., Barre-Sinoussi F., Chun T.W., Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180.
41. Tukey R.H., Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. 2000, 40:581-616.
42. Uchaipichat V., Mackenzie P.I., Elliot D.J., Miners J.O. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2006, 34:449-456.
43. Uchaipichat V., Mackenzie P.I., Guo X.H., Gardner-Stephen D., Galetin A., Houston J.B., Miners J.O. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos. 2004, 32:413-423.
44. Vahey M., Nau M.E., Barrick S., Cooley J.D., Sawyer R., Sleeker A.A., Vickerman P., Bloor S., Larder B., Michael N.L., Wegner S.A. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J. Clin. Microbiol. 1999, 37:2533-2537.
45. Wienkers L.C., Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 2005, 4:825-833.
46. Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., Peterkin V., Koup J.R., Ball S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC(i)/AUC) ratios. Drug Metab. Dispos. 2004, 32:1201-1208.